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OBJECTIVES With the present studies we sought to determine how treatment with nitroglycerin (NTG)
affects endothelial function, oxidative stress and nitric oxide (NO)-downstream signaling in
Watanabe heritable hyperlipidemic rabbits (WHHL).
BACKGROUND In vitro experiments have demonstrated potent antiatherosclerotic effects of NO suggesting
that treatment with NO-donors such as NTG could compensate for the diminished
availability of endothelial NO. Nitric oxide may, however, not only be scavenged by reaction
with endothelium-derived superoxide but also form the potent oxidant and inhibitor of
vascular function, peroxynitrite (ONOO-).
METHODS Watanabe heritable hyperlipidemic rabbits were treated for three days with NTG patches.
Normolipidemic New Zealand White rabbits (NZWR) served as controls. Endothelial
function was assessed ex vivo with organ chamber experiments and vascular superoxide was
quantified using lucigenin (5 and 250 M) and CLA-enhanced chemiluminescence. Vascular
ONOO- formation was determined using nitrotyrosine antibodies. The activity of the
cGMP-dependent kinase (cGK-I) was assessed by determining the phosphorylation of
vasodilator-stimulated phosphoprotein VASP (P-VASP).
RESULTS Nitroglycerin treatment caused endothelial dysfunction in NZWR and WHHL, associated
with an increase in superoxide and ONOO- production and a substantial drop in cGK-I
activity. In vivo NTG-treatment decreased lipophilic antioxidants (- and -carotene) in
NZWR and WHHL. Treatment of NZWR with NTG also decreased plasma extracellular
superoxide dismutase (EC-SOD)-activity.
CONCLUSIONS Nitroglycerin treatment of WHHL with exogenous NO worsens rather than improves
endothelial dysfunction secondary to increased formation of superoxide and/or peroxynitrite
leading to decreased cGK-I activity. The decrease in plasma levels of - and -carotene may
be at least in part due to a decrease in EC-SOD activity. (J Am Coll Cardiol 2002;40:
1356–63) © 2002 by the American College of Cardiology Foundation
Coronary artery disease is associated with endothelial dys-
function, a phenomenon, which has been attributed to a
decreased availability of the endothelium-derived relaxing
factor, nitric oxide (NO). In vitro, NO has been shown to
possess potent antiatherosclerotic properties. Thus, one may
conceptualize that treatment with an exogenous source of
NO (e.g., nitroglycerin [NTG]) could compensate for the
diminished endothelial availability of NO in atherosclerosis,
thereby preventing the consequences of endothelial dys-
function such as increased propensity of vasoconstriction
and platelet activation. Nitric oxide, however, rapidly reacts
with vascular cell derived superoxide (O2
-) leading to the
formation of peroxynitrite (ONOO-), a potent oxidant and
potential mediator of vascular injury (1). Therefore, despite
potent antiatherosclerotic properties demonstrated in vitro,
it remains to be established whether in the setting of
increased endothelial O2
- production such as hypercholes-
terolemia treatment of hypercholesterolemic animals with
NO in vivo may have beneficial or deleterious effects with
respect to the atherosclerotic process.
When given acutely, NTG has potent vasodilatory and
platelet-inhibitory effects and is successfully used for the
treatment of angina pectoris and patients with post-
myocardial infarction angina. Chronic NTG treatment,
however, is limited due to the rapid development of nitrate
tolerance. Recently, we have defined a new mechanism
partially responsible for tolerance and cross-tolerance to
other endothelium-dependent and -independent vasodila-
tors (2). Chronic NTG treatment of rabbits and rats led to
tolerance and cross-tolerance development associated with
increased O2
- production due to activation of an NADH-
driven oxidase (3) and due to NOS III uncoupling (4). Early
stages of atherosclerosis are also associated with increased
endothelial O2
- production in hypercholesterolemic animals
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and in patients, a phenomenon which seems to be related, at
least in part, to the activation of NADH-dependent oxi-
dases (3) and an uncoupled NOS III (4). Hyperlipidemia as
well as nitrate tolerance have been recently shown to be
associated with decreased cyclic guanosine monophosphate-
dependent protein kinase activity as indicated by marked
decreases in the phosphorylation of vasodilator-stimulated
phosphoprotein (P-VASP) (5–7). Reduction of oxidative
stress by concomitant treatment of hyperlipidemic animals
with AT1 receptor blockers (5) or of NTG-treated animals
with vitamin C (6) resulted in a marked improvement in
endothelial function, a reduction in O2
- levels as well as in
a restoration of P-VASP.
The aim of the present study therefore was to test
whether in vivo treatment of hypercholesterolemic animals
with NTG: 1) beneficially or detrimentally influence endo-
thelial dysfunction, 2) beneficially or detrimentally may
influence oxidative stress parameters in plasma such as the
extracellular superoxide dismutase (EC-SOD) and anti-
oxidants - and -carotene, and 3) how these changes
may influence the activity of the cyclic guanosine
monophosphate-dependent protein kinase-I (cGK-I).
METHODS
Animal model and vessel preparation. Forty male New
Zealand White rabbits (NZWR) and 40 male Watanabe
heritable hyperlipidemic (WHHL) rabbits (age three
months) weighing 2 to 4 kg were studied. Four groups were
formed: an untreated control group (no NTG, n  20);
control animals treated with transdermal NTG for three
days (0.5 mg/h; for three days [2]; n 20); a WHHL group
(n  20), and a WHHL group treated with transdermal
NTG (n  20). On the day of the study, blood samples
were drawn for determination of plasma lipids and li-
pophilic antioxidants. Aortic rings were suspended in indi-
vidual organ chambers and relaxations to acetylcholine
(ACh) and NTG were tested as described (2).
Oxidative fluorescent microtopography. The oxidative
fluorescent dye hydroethidine (2  10-6 M) was used to
evaluate the in situ concentration of O2
- as described
recently (6).
Estimation of basal vascular superoxide production.
Relative rates of O2
- production in intact vascular tissue
were measured using lucigenin (5 M [8] and 250 M [2])
and CLA-derived chemiluminescence (9).
Determination of plasma EC-SOD activity. The super-
oxide dismutase (SOD) enzymatic activity was determined
with the direct spectrophotometric method employing KO2
(10) the cyanide-sensitive isoenzymes CuZn-SOD and
EC-SOD and the resistant Mn-SOD, 3 mM cyanide was
used. To compensate for hemolysis during tapping and
handling of the samples, the plasma hemoglobin contents
were determined. This allowed calculation of CuZn-SOD
released to plasma due to hemolysis using the CuZn-SOD
content per mg hemoglobin of rabbit erythrocytes, and the
results were subtracted from the measured plasma SOD
activities. CuZn-SOD accounts for 4% of the plasma
SOD activity in rabbits (11) and the cyanide-sensitive
activities of the plasma samples were therefore assumed to
derive from EC-SOD.
Immunohistochemistry. Aortic sections (n  4 from each
group) were stained with a monoclonal antiserum to nitro-
tyrosine using a previously described method (12). The
grades were assessed by two independent, blinded observers:
Grade 0  no staining, Grade 1  focal staining (few
scattered cells representing 25% of the total number of
cells), Grade 2 diffuse weak staining (most of the cells
show weak staining), Grade 3  diffuse moderate staining
and Grade 4  diffuse strong staining. In case of disagree-
ment the average value of the grading was taken.
Detection of cGK-I expression, cGK-I activity and
VASP serine239 phosphorylation (P-VASP). Aortic seg-
ments from NZWR and WHHL with and without NTG
treatment were frozen and homogenized in liquid nitrogen.
SDS-PAGE electrophoresis and electroblotting was per-
formed as described. Immunoblotting was performed with a
polyclonal antibody against cGK-I and a mouse monoclonal
antibody (16C2) specific for P-VASP, as described recently
(5).
Analytical measurements in plasma. Lipids were deter-
mined using enzymatic tests (Boehringer Mannheim,
Mannheim, Germany). Lipophilic antioxidants such as
-carotene, -carotene were measured as described (13).
Materials. All chemicals were purchased from Sigma (De-
isenhofen, Germany) or Merck (Darmstadt, Germany).
Statistical analysis. Results are expressed as mean SEM.
The ED50 value for each experiment was obtained by logit
transformation. To compare O2
- production, cGK-I ex-
pression and P-VASP in normal and hyperlipidemic vessels
with and without NTG-treatment, two-way analysis of
variance was employed. To compare the EC-SOD levels
from NZWR before and after NTG treatment a paired
Student t-test was used. Comparisons of vascular responses
were performed using multivariate analysis of variance.
Scheffe´ post-hoc test was used to examine differences
Abbreviations and Acronyms
Ach  acetylcholine
cGK-I  cyclic guanosine monophosphate-dependent
protein kinase I
EC-SOD  extracellular superoxide dismutase
LDCL  Lucigenin-derived chemiluminescence
NO  nitric oxide
NOS  nitric oxide synthase
NTG  nitroglycerin
NZWR  New Zealand White rabbits
O2
·-  superoxide
ONOO-  peroxynitrite
P-VASP  phosphorylated vasodilator stimulated
phosphoprotein
WHHL  Watanabe heritable hyperlipidemic rabbits
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between groups when significance was indicated. With
respect to plasma parameters, group differences in variables
were analyzed by a two-way analysis of variance. Spearman’s
rank correlation coefficients were calculated to evaluate
relationships between variables. The p values  0.05 were
considered statistically significant.
RESULTS
Effects of NTG treatment on vasodilator responses to
ACh and NTG. Treatment of NZWR with NTG for
three days caused a significant degree of endothelial dys-
function and worsened endothelial dysfunction in WHHL
(Fig. 1A, Table 1). The degree of tolerance achieved with
NTG was comparable in both animal groups (Fig. 1B,
Table 1).
Effects of NTG treatment on hydroethidine staining in
endothelial and smooth muscle cells of NZWR and
WHHL. Hydroethidine staining in endothelial and in
smooth muscle cells was higher in WHHL compared to
controls. NTG treatment increased hydroethidine staining
in NZWR as well as in WHHL (Fig. 2).
Effects of NTG treatment on lucigenin and CLA chemi-
luminescence. The Lucigenin-derived chemiluminescence
(LDCL) was more than two-fold higher in WHHL and
NTG-treated NZWR compared to control. Treatment of
hyperlipidemic WHHL with NTG reduced the vascular
LDCL (250 M) to control levels (Fig. 3). A similar
pattern was observed using lucigenin concentrations of 5
M. Using CLA, however, we failed to detect a significant
decrease in the chemiluminescence signals of aortas from
WHHL treated with NTG.
Effects of NTG treatment on EC-SOD activity. Three
day NTG treatment reduced the plasma EC-SOD activity
significantly from 1,279  39 U/ml to 1,129  36 U/ml
(p  0.05).
Figure 1. Effects of three days nitroglycerin (NTG) treatment on acetylcholine (ACh) (A) and NTG concentration-response curve (B). Data are expressed
as mean  SEM of 8 to 10 experiments. *p  0.05 versus control, †p  0.05 versus WHHL. Black circles  control; black triangles  control  NTG;
open circles  WHHL; open triangles  WHHL  NTG. WHHL  Watanabe heritable hyperlipidemic rabbits.
Table 1. Effects of NTG Treatment on Potency (ED50) and
Efficacy (Maximal Relaxations) to Endogenous and Exogenous
Nitrovasodilators in Aortas from Untreated and NTG-Treated
Animals
Group
Potency ED50 (-logM)
Efficacy Max.
Relaxation (%)
ACh NTG ACh NTG
Control 7.33  0.07 7.65  0.10 94  3 97  2
Control  NTG 6.98  0.05* 7.14  0.13* 75  2* 70  4*
WHHL 7.08  0.09 7.56  0.04 71  3* 98  1
WHHL  NTG 6.91  0.10* 6.98  0.11*† 47  3*† 77  11*†
*p  0.05 vs. control, †p  0.05 vs. WHHL. ED50 are concentrations, which
produced 50% of maximal relaxation to each drug. Each value is the mean  SEM
of 10 to 12 experiments.
ACh  acetylcholine; NTG  nitroglycerin; WHHL  Watanabe heritable
hyperlipidemic rabbits.
Figure 2. Effect of three days nitroglycerin (NTG) treatment on vascular
superoxide in aortas from New Zealand white rabbits (NZWR) and
Watanabe heritable hyperlipidemic rabbits (WHHL) as detected with
hydroethidine. Vessels were labeled with the dye hydroethidine, which
produces a red fluorescence when oxidized to ethidium bromide by
superoxide. Data are representative for n  4 experiments. A  adventitia;
E  endothelium; M  media.
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Effects of NTG treatment on vascular nitrotyrosine
staining. Immunohistochemistry with a monoclonal anti-
body showed very low nitrotyrosine staining in vessels from
NZWR, which was slightly but not significantly increased by
in vivo treatment of NZWR with NTG. In vessels from
WHHL we found a significant stronger nitrotyrosine staining,
which was further increased by NTG treatment, especially in
the endothelium and subendothelial space (Figs. 4 and 5).
Influence of in vivo NTG treatment on cGK-I expres-
sion and on P-VASP. Compared to NZWR we estab-
lished a marked drop in P-VASP in aortas from WHHL.
Likewise, in vivo NTG treatment caused a marked decrease
in P-VASP in NZWR without altering cGK-I expression.
Treatment of WHHL with NTG almost completely abol-
ished P-VASP (Fig. 6).
Effects of NTG treatment on plasma lipid and lipophilic
antioxidant levels. Plasma lipid levels were elevated in
WHHL compared to control animals (Table 2). No differ-
ence in total lipids between WHHL rabbits and WHHL
treated with NTG was found. Lipophilic antioxidants such
as lipid-normalized -carotene and -carotene were signif-
icantly lower in WHHL compared to controls. NTG
treatment caused a further decrease in -carotene and
-carotene (Fig. 7).
DISCUSSION
The present study shows that early stages of atherosclerosis
are characterized by endothelial dysfunction associated with
increased vascular O2
- production. In vivo treatment of
Figure 3. Effects of three days nitroglycerin (NTG) treatment on vascular superoxide production in aortas from control rabbits (C) and Watanabe heritable
hyperlipidemic rabbits (WHHL) as estimated by lucigenin (250 and 5 M) and CLA-enhanced chemiluminescence. The data are presented as mean 
SEM (n  4 to 10 per group). *p  0.05 versus control, †p  0.05 versus WHHL.
Figure 4. Effects of three days nitroglycerin (NTG) treatment on immu-
noreactivity for nitrotyrosine in vessels from control rabbits without (A)
and with nitroglycerin treatment (B) and hyperlipidemic animals without
(C) and with NTG treatment (D). Please note that NTG treatment of
hyperlipidemic animals caused a marked increase in nitrotyrosine staining
in the endothelium and the subendothelial space (brown staining).
Figure 5. Immunoreactivity for nitrotyrosine in vessels from control (C)
and hyperlipidemic (WHHL) rabbits with and without nitroglycerin
(NTG) treatment. Immunohistochemical grades were determined as de-
scribed in methods. Data are presented as mean  SEM from 4 to 6
experiments. *p  0.05 versus control, †p 0.05 versus WHHL.
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WHHL with NTG increased rather than decreased oxida-
tive stress and simultaneously worsened endothelial func-
tion. Accordingly we found that cGK-I activity as assessed
with P-VASP was substantially reduced in aortas from
WHHL treated with NTG. Treatment of WHHL with
NTG also caused a marked increase in nitrotyrosine staining
in the endothelium and the subendothelial space compatible
with increased ONOO- formation, a phenomenon, which
was associated with a consumption of - and -carotene in
rabbit plasma.
Increased superoxide production in atherosclerosis.
Hypercholesterolemia has been shown to be associated with
endothelial dysfunction in vivo. The mechanisms underly-
ing this phenomenon are multifactorial but likely involve at
least in part enhanced degradation of NO secondary to an
activation of O2
- producing enzymes such as the xanthine
oxidase (14), the NAD(P)H-oxidase (15) and an uncoupled
NOS III (5). Decreased vascular NO bioactivity secondary
to increased endothelial production of reactive oxygen
species may have important implications with respect to the
progression of the atherosclerotic process. Nitric oxide has
been shown to possess multifaceted antiatherosclerotic
properties. It inhibits platelet aggregation, prevents the
expression of adhesion molecules by the endothelium, in-
hibits the adhesion of neutrophils to the endothelium via its
ability to scavenge lipid peroxyl radicals and in turn inhibit
NFB-mediated gene expression of VCAM-1 and to a
lesser extent ICAM. Further evidence for potential antiath-
erosclerotic properties of NO was provided by experiments
showing that inhibition of NOS III dramatically increases
neointimal formation in cholesterol-fed rabbits (16). Thus,
one may conceptualize that exogenous NO (e.g., via admin-
istration of organic nitrates) could compensate for the
diminished endothelial net NO release in atherosclerosis.
Peroxynitrite and the tolerance and cross-tolerance phe-
nomenon. Treatment of hyperlipidemic animals for three
days with NTG indeed significantly reduced the lucigenin-
derived chemiluminescence signal in intact vessels, but at
the same time, however, worsened endothelial function.
One explanation for this apparent paradox could be in-
creased vascular ONOO- formation as a consequence of
NTG treatment of animals that already have increased
endothelial O2
--production. The facile reaction between
Table 2. Lipid Profile of Controls and Hypercholesterolemic
(WHHL) Rabbits With and Without NTG Treatment
Control
Control 
NTG WHHL
WHHL 
NTG
Total cholesterol
(mg/dl)
91  19 48  8 577  30* 574  31*
Triglycerides
(mg/dl)
122  12 166  24 333  21* 291  14*
HDL cholesterol
(mg/dl)
23  1 23  6 13  1* 13  2*
Data are mean  SEM of 8 to 12 samples. *p  0.05 vs. controls.
Abbreviations as in Table 1.
Figure 6. Effects of nitroglycerin (NTG) treatment on the expression of the cGMP dependent protein kinase (cGK-I) and the vasodilatory stimulated
phosphoprotein (P-VASP) in NZWR and WHHL. A, upper panel shows original blots of aortas from NZWR and WHHL with and without NTG
treatment. B, the lower panel shows the densitometric quantification. Data are presented as mean  SEM from 4 experiments *p  0.05 versus control.
Abbreviations as in Figure 2.
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NO and O2
- ( 6.7 109 M-1s-1) is about 3 times faster
than the dismutation of O2
- to H2O2 by SOD. The
reaction product between NO and O2
- not only lowers the
steady state concentration of NO but at the same time yields
ONOO-, a product of potential pathophysiological signifi-
cance. The ONOO- in high concentrations is cytotoxic and
may cause oxidative damage to proteins, lipids and deoxyri-
bonucleic acid. The ONOO- formation has been shown to
cause endothelial dysfunction and nitration of tyrosine
residues that may lead to a functional inhibition of the
prostacyclin synthase (17). Indeed, with the present studies
we provide evidence for increased vascular ONOO- forma-
tion by the demonstration of a broad nitrotyrosine band in
vessels from WHHL treated with NTG. Interestingly
nitrotyrosine formation was restricted to the endothelium
and the subendothelial space.
There is a growing body of evidence showing that
increased vascular ONOO- formation may also have dele-
terious consequences for the function of the NOS III by
oxidizing the cofactor tetrahydrobiopterin (BH4) to dihy-
drobiopterin (BH2) (18). The resulting intracellular BH4
deficiency may lead to an uncoupling of NOS III (18).
Thus, NTG therapy may switch NOS III from a NO to a
O2
- producing enzyme, which may further increase oxida-
tive stress in vascular tissue in a positive feedback fashion
(19). Indeed, an uncoupled NOS III has recently been
demonstrated in an animal model of nitrate tolerance since
an inhibitor of NOS III, NG-nitro-L-arginine was able to
significantly reduce vascular O2
- in tolerant vessels (4). In
addition, supplementation of NTG-treated rats with BH4
was able to reverse NTG-induced endothelial dysfunction
(20). Thus, the demonstration of endothelial dysfunction in
our animal model goes parallel with data obtained from
studies where NTG treatment of patients (21) and also
healthy volunteers (22) was able to cause endothelial dys-
function. The concept of an uncoupled NOS in the setting
of tolerance has been recently suggested by studies with
chronically NTG-treated volunteers, where endothelial dys-
function but also nitrate tolerance was corrected by applying
folic acid (22), a compound that restores NOS III function
in vitro by increasing depleted intracellular BH4 levels (23).
Evidence for an uncoupled NOS III has been recently
demonstrated also in two experimental models of athero-
sclerosis (5,18) as well as in hyperlipidemic patients (24). It
is therefore tempting to speculate that a ONOO- -induced
endothelial dysfunction during NTG therapy is at least in
part responsible for the worsening of endothelial function in
both animal groups and that this is secondary to NOS III
uncoupling.
In contrast to data obtained from the lucigenin assay, we
found that the CLA-derived chemiluminescence signal
from hyperlipidemic animals treated with NTG was not
different from WHHL aortas without NTG treatment.
This observation, however, is not surprising since CLA
represents a chemiluminescent substance which may detect
O2
- as well as ONOO- (25). Therefore, although the
interaction between O2
- and NO decreases O2
- steady state
levels, the simultaneously formed ONOO- may keep the
CLA signal elevated.
NTG therapy decreases the activity of the cGMP-
dependent protein kinase in hyperlipidemic WHHL.
Studies with cGK-I deficient mice have recently been
shown to cause a complete disruption of the NO/cGMP
signaling pathway in the vascular smooth muscle (26)
indicating that the activity and/or expression of cGK-I
critically modulate NTG-induced vasorelaxation. To assess
whether the expression of cGK-I was affected by hyperlip-
idemia and/or NTG-treatment, we analyzed the expression
of this protein by Western blotting. We could not detect
any changes in cGK-I expression in aortas from NTG-
treated NZWR or WHHL compared to the control group
indicating that a down-regulation of cGK-I does not
significantly contribute to tolerance and cross-tolerance in
our model.
Figure 7. Effects of three days nitroglycerin (NTG) treatment of control (C) and hyperlipidemic (WHHL) rabbits on plasma - and -carotene levels. Data
are presented as mean  SEM from 8 to 12 experiments. *p  0.05 versus control. †p  0.05 versus WHHL.
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To assess the activity of cGK-I in intact aortic tissue from
tolerant and non-tolerant animals, we studied the phos-
phorylation of the 46/50-kDa vasodilator-stimulated phos-
phoprotein (VASP) at serine239. The VASP is a well-
characterized substrate for cGK-I and cAMP-dependent
protein kinase (cAK) in platelets, endothelial and vascular
smooth muscle cells. Activation of cGK-I in vascular tissue
can be analyzed by specific monoclonal antibodies directed
against the phospho-VASP form at serine239 (P-VASP)
(5). In the present studies, we found in vessels from WHHL
a striking reduction in P-VASP as shown previously (5).
Likewise, as shown before, treatment of animals and pa-
tients with NTG resulted in a marked decrease in vascular
P-VASP (6,7) levels. Treatment of hypercholesterolemic
animals with NTG almost completely abolished vascular
P-VASP levels. The decrease in P-VASP induced by
chronic NTG treatment was not due to decreased availabil-
ity of this cGK-I substrate, since total VASP expression at
the protein level was not different in tolerant and non-
tolerant aorta. Recently we found that endothelial dysfunc-
tion in WHHL was associated with increased vascular O2
-,
as well as with decreased P-VASP. In this particular
study, treatment of WHHL with the AT1 receptor blocker
irbesartan improved endothelial dysfunction, reduced vas-
cular O2
- and simultaneously increased vascular NO-
bioavailability and increased P-VASP (5). These observa-
tions indicate again, that the level of vessel P-VASP closely
follows changes in endothelial function and vascular oxida-
tive stress. It is therefore reasonable to conclude that the
decrease in P-VASP in control and WHHL treated with
NTG is at least in part secondary to NTG-induced in-
creases in reactive oxygen species within the vascular tissue.
Effects of in vivo NTG treatment on plasma: - and
-carotene. In the present study we also found that plasma
levels of two antioxidants, - and -carotene, were signif-
icantly decreased in WHHL after NTG-treatment. These
data are in agreement with our recent finding that both -
and -carotene are significantly lower in hyperlipidemic
patients and patients with coronary artery disease than in
healthy controls (27). Interestingly, Panasenko et al. (28)
have shown that ONOO- can cause a marked loss of - as
well as -carotene. These findings indicate that carotenoids
can efficiently react with ONOO- and perform the role of
scavengers of ONOO- in vivo. Therefore the consumption
of - as well as -carotene in plasma may be a consequence
of the observed increase in ONOO- formation within
vascular tissue in response to chronic NTG treatment. In
order to further differentiate between a direct effect of NTG
on carotene levels and consumption of carotenes due to
enhanced oxidative stress in plasma we examined the effect
of in vivo NTG treatment on plasma EC-SOD activity.
Interestingly, treatment of NZWR for three days resulted in
a significant decrease in plasma EC-SOD. The reason for
this finding is not clear, but may be related to NTG-
induced formation of reactive oxygen species.
Conclusions. Taken together, the present studies demon-
strate that in vivo treatment of hyperlipidemic animals with
NTG increases rather than decreases reactive oxygen species
in vessels and in plasma leading to nitrate tolerance, to a
decrease cGK-I activity and to a strong increase in ONOO-
formation within the endothelial cell layer. Thus, NTG-
induced oxidative stress may explain, at least in part, why
NTG-treatment worsens endothelial function as well as
prognosis in patients with coronary artery disease.
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